Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1723608 | 1.00 | HTT (0.42) | HTTPOLBALDH1A1LMNAGRM2 | |
| SCHEMBL3328496 | 1.00 | HTT (0.42) | HTTPOLBALDH1A1LMNAGRM2 | |
| SCHEMBL591467 | 0.88 | GRM2 (0.41) | HTTGRM2TRPV1F10 | |
| SCHEMBL1712464 | 0.88 | GRM2 (0.41) | HTTGRM2TRPV1F10 | |
| SCHEMBL1712414 | 0.88 | HTT (0.43) | HTTPOLBALDH1A1LMNAGRM2 | |
| SCHEMBL1712026 | 0.88 | GRM2 (0.41) | HTTGRM2TRPV1F10 | |
| SCHEMBL1222807 | 0.88 | HTT (0.43) | HTTPOLBALDH1A1LMNAGRM2 | |
| SCHEMBL2239583 | 0.88 | HTT (0.43) | HTTPOLBALDH1A1LMNAGRM2 | |
| SCHEMBL1711810 | 0.86 | HTT (0.41) | HTTPOLBALDH1A1LMNAGRM2 | |
| SCHEMBL1711838 | 0.86 | HTT (0.41) | HTTPOLBALDH1A1LMNAGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916573-B2 | Quinazoline-2,4-dione derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-12-23 | — | — | US | disclosed |
| US-20140171425-A1 | QUINAZOLINE-2,4-DIONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-06-19 | — | — | US | disclosed |
| US-20100137290-A1 | OXAZOLIDINONE ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137290-A1 | OXAZOLIDINONE ANTIBIOTIC DERIVATIVES | OXA1L, XDH, CCNY | HTT 3101/4885POLB 453/4885ALDH1A1 1130/4885 |
| US-20140171425-A1 | QUINAZOLINE-2,4-DIONE DERIVATIVES | NQO2, H1-3, H1-0 | HTT 2518/4885POLB 2023/4885ALDH1A1 1666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.